Catalent, Inc. (“Catalent”) (NYSE: CTLT), today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $650 million in aggregate principal amount of 3.500% senior unsecured notes due 2030 (the “Notes”) at par, which represents an increase of $200 million from the offering size previously announced.
September 23, 2021
· 6 min read